
About Krebs Biochemicals
Krebs Biochemicals is a publicly listed company based in Hyderabad (India) founded in 1991. Biotech processes are developed for medicine and agriculture uses. The company has 28 employees. Its Indian entity Krebs Biochemicals And Industries Limited reported revenue of βΉ25.76 Cr. Krebs Biochemicals offers products and services including Biotech Processes. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Similar companies include Laurus Labs, Symbiotec and SeQuent; 2 of its 3 listed similar companies have raised funding.
Company details
Founded in 1991 and based in Hyderabad, India, Krebs Biochemicals operates in the biopharma sector. Commercially viable biotech processes are developed for applications in medicine and agriculture. Current manufacturing includes Androstenedione as a steroid intermediate, along with Lovastatin and Simvastatin for anti-cholesterol treatments. Products under development encompass amlodipine and Telmisartan for anti-hypertension, Cetirizine for anti-histamine effects, Orlistat for anti-obesity, Serratiopeptidase for anti-inflammatory purposes, and Phenylephrine for cold and cough relief.
- Headquarters Hyderabad, India
- Employees 28
- Stage Public
- SectorsHealthcare
- Website krebsbiochem.com
- Social LinkedIn
- Legal Name Krebs Biochemicals & Industries Ltd.
- Market Cap₹127 Cr
KREBSBIO · NSE
- Share Price₹57.15
-3.12% today
- Revenue₹23.73 Cr
FY 2025-26 · -45.2% YoY
- EBITDA−₹5.45 Cr
Margin -23.0%
- Net Profit−₹16.93 Cr
FY 2025-26 · +37.4% YoY
- Employee Count28
Associated legal entities of Krebs Biochemicals
Krebs Biochemicals operates through Krebs Biochemicals And Industries Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Krebs Biochemicals And Industries Limited Listed CIN L24110AP1991PLC103912 | Active | 02 Dec 1991 | Anakapalli, Telangana | ₹25.8 Cr | 335 | 11 | View details |
Products & Services of Krebs Biochemicals
Krebs Biochemicals offers a comprehensive portfolio of products and services, including Biotech Processes.
Develops processes for medicine and agriculture applications
Board of directors of Krebs Biochemicals And Industries Limited (Krebs Biochemicals)
Krebs Biochemicals And Industries Limited is the primary company behind Krebs Biochemicals. The board of Krebs Biochemicals And Industries Limited currently have 8 directors; the longest-serving is Ravi Ravindranath Tagore, appointed in 1992. 27 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Ravi Ravindranath Tagore DIN 00272977 | Director | 12 Oct 1992 | 34 yrs 1 mo | Krebs Biochemicals And Industries Limited |
| Avinash Ravi DIN 01616152 | Director | 13 Aug 2015 | 11 yrs 3 mo | Krebs Biochemicals And Industries Limited |
| Pabitrakumar Kalipada Bhattacharyya DIN 07131152 | Director | 10 Aug 2023 | 3 yrs 3 mo | Krebs Biochemicals And Industries Limited |
| Popatlal Mukanchand Kathariya DIN 00281395 | Director | 04 Feb 2025 | 1 yr 9 mo | Krebs Biochemicals And Industries Limited |
| Dipti Chinubhai Shah DIN 07995542 | Director | 04 Feb 2025 | 1 yr 9 mo | Krebs Biochemicals And Industries Limited |
| Satya Prakash Chigurupati DIN 00721318 | Director | 04 Feb 2025 | 1 yr 9 mo | Krebs Biochemicals And Industries Limited |
| Sumanth Karlapudi DIN 09188185 | Director | 04 Feb 2025 | 1 yr 9 mo | Krebs Biochemicals And Industries Limited |
| Manish Kumar Jain DIN 06477976 | Managing Director | 07 Aug 2025 | 1 yr 3 mo | Krebs Biochemicals And Industries Limited |
IPO & Listings of Krebs Biochemicals
Krebs Biochemicals is a publicly listed company on the NSE with ticker symbol KREBSBIO in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 May 2000
- Listed onBSE: 524518
- Listed entityKrebs Biochemicals & Industries Ltd.
- Exchange sectorHealth technology
- ISININE268B01013
- Share price₹60.41 (+5.45% on the day) · 2026-10-14
- Market capitalisation₹122 Cr
- EPS (diluted, trailing year)₹-6.54
- Volume (last session)47,475
Financials of Krebs Biochemicals
Exchange-reported figures of Krebs Biochemicals And Industries Limited, the listed company behind Krebs Biochemicals (NSE: KREBSBIO).
Financial Highlights
FY 2025-26 Β· StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 23.73 | 43.31 | 50.42 | 52.13 | 59.70 | 53.70 | 33.41 |
| Revenue growth | -45.2% | -14.1% | -3.3% | -12.7% | +11.2% | +60.7% | - |
| EBITDA | (5.45) | (15.03) | (8.71) | (15.80) | (33.99) | (17.56) | (18.56) |
| EBITDA margin | -23.0% | -34.7% | -17.3% | -30.3% | -56.9% | -32.7% | -55.6% |
| Profit before tax | (16.93) | (26.92) | (19.72) | (24.71) | (44.52) | (28.34) | (28.87) |
| Net profit | (16.93) | (27.06) | (19.72) | (24.71) | (44.52) | (28.34) | (28.88) |
| Net profit margin | -71.3% | -62.5% | -39.1% | -47.4% | -74.6% | -52.8% | -86.4% |
| EPS (βΉ) | (7.85) | (12.49) | (9.15) | (11.45) | (20.65) | (14.45) | (16.04) |
| Balance sheet | |||||||
| Total assets | 111 | 116 | 127 | 136 | 122 | 122 | 91.37 |
| Net worth | (32.76) | (16.24) | 10.78 | 30.54 | 54.91 | (12.73) | 5.00 |
| Total debt | 94.84 | 82.21 | 63.68 | 53.37 | 13.10 | 81.14 | 36.22 |
| Cash & bank | 0.13 | 0.14 | 0.14 | 0.09 | 0.10 | 0.71 | 0.17 |
| Net working capital | (42.16) | (42.31) | (34.21) | (22.91) | (32.41) | (16.18) | (23.57) |
| Cash flow | |||||||
| Cash from operations | (1.92) | (7.89) | 2.36 | (24.71) | (17.22) | (14.57) | (35.50) |
| Cash from investing | (3.64) | (4.97) | (7.82) | (12.65) | (22.90) | (22.55) | (10.22) |
| Cash from financing | 5.54 | 12.86 | 5.50 | 37.34 | 39.51 | 37.66 | 28.58 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.79 | 6.98 | 6.81 | 7.27 | 4.17 | 5.48 | 6.10 | 11.47 |
| Revenue growth (YoY) | +38.9% | +27.4% | +11.6% | -36.6% | -67.6% | -57.5% | - | - |
| Other income | 0.04 | 0.16 | 2.00 | 0.00 | 0.01 | 0.01 | 0.34 | 0.25 |
| Total expenses | 7.72 | 6.16 | 7.68 | 6.98 | 6.96 | 7.57 | 11.51 | 16.18 |
| EBITDA | (1.93) | 0.82 | (0.87) | 0.29 | (2.79) | (2.09) | (5.41) | (4.71) |
| EBITDA margin | -33.3% | +11.7% | -12.8% | +4.0% | -66.9% | -38.1% | -88.7% | -41.1% |
| Depreciation | 1.61 | 1.59 | 1.57 | 1.63 | 1.62 | 1.60 | 1.57 | 1.72 |
| Interest | 1.90 | 1.88 | 1.91 | 1.79 | 1.73 | 1.65 | 1.61 | 1.56 |
| Profit before tax | (5.40) | (2.49) | (2.35) | (3.13) | (6.13) | (5.33) | (8.25) | (7.74) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.79 | 6.98 | 6.81 | 7.27 | 4.17 | 5.48 | 6.10 | 11.47 |
| Revenue growth (YoY) | +38.9% | +27.4% | +11.6% | -36.6% | -67.6% | -57.5% | - | - |
| Other income | 0.04 | 0.16 | 2.00 | 0.00 | 0.01 | 0.01 | 0.34 | 0.25 |
| Total expenses | 7.72 | 6.16 | 7.68 | 6.98 | 6.96 | 7.57 | 11.51 | 16.18 |
| EBITDA | (1.93) | 0.82 | (0.87) | 0.29 | (2.79) | (2.09) | (5.41) | (4.71) |
| EBITDA margin | -33.3% | +11.7% | -12.8% | +4.0% | -66.9% | -38.1% | -88.7% | -41.1% |
| Depreciation | 1.61 | 1.59 | 1.57 | 1.63 | 1.62 | 1.60 | 1.57 | 1.72 |
| Interest | 1.90 | 1.88 | 1.91 | 1.79 | 1.73 | 1.65 | 1.61 | 1.56 |
| Profit before tax | (5.40) | (2.49) | (2.35) | (3.13) | (6.13) | (5.33) | (8.25) | (7.74) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 23.73 | 43.31 | 50.42 | 52.13 | 59.70 | 53.70 | 33.41 |
| Revenue growth | -45.2% | -14.1% | -3.3% | -12.7% | +11.2% | +60.7% | - |
| Other income | 2.03 | 0.71 | 0.45 | 0.62 | 1.16 | 0.62 | 0.37 |
| Total expenses | 29.18 | 58.34 | 59.13 | 67.93 | 93.69 | 71.26 | 51.97 |
| Employee cost | 0.00 | 16.30 | 16.17 | 15.54 | 14.96 | 15.30 | 14.56 |
| EBITDA | (5.45) | (15.03) | (8.71) | (15.80) | (33.99) | (17.56) | (18.56) |
| EBITDA margin | -23.0% | -34.7% | -17.3% | -30.3% | -56.9% | -32.7% | -55.6% |
| Depreciation | 6.42 | 6.69 | 6.77 | 6.56 | 6.30 | 5.12 | 4.68 |
| Interest | 7.09 | 5.91 | 4.69 | 2.97 | 5.39 | 6.28 | 6.00 |
| Profit before tax | (16.93) | (26.92) | (19.72) | (24.71) | (44.52) | (28.34) | (28.87) |
| Tax | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net profit | (16.93) | (27.06) | (19.72) | (24.71) | (44.52) | (28.34) | (28.88) |
| Net profit margin | -71.3% | -62.5% | -39.1% | -47.4% | -74.6% | -52.8% | -86.4% |
| EPS (βΉ) | (7.85) | (12.49) | (9.15) | (11.45) | (20.65) | (14.45) | (16.04) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 152 | 152 | 152 | 152 | 152 | 49.62 | 48.00 |
| Reserves & surplus | (184) | (168) | (141) | (121) | (96.65) | (66.52) | (43.00) |
| Shareholders' funds (net worth) | (32.76) | (16.24) | 10.78 | 30.54 | 54.91 | (12.73) | 5.00 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 71.14 | 35.51 |
| Unsecured loans | 94.84 | 82.21 | 63.68 | 53.37 | 13.10 | 10.00 | 0.71 |
| Total debt | 94.84 | 82.21 | 63.68 | 53.37 | 13.10 | 81.14 | 36.22 |
| Total liabilities | 111 | 116 | 127 | 136 | 122 | 122 | 91.37 |
| Assets | |||||||
| Gross block | 314 | 314 | 312 | 303 | 288 | 261 | 243 |
| Net block | 142 | 146 | 150 | 147 | 139 | 118 | 105 |
| Capital work in progress | 1.59 | 3.09 | 2.00 | 4.09 | 8.38 | 11.94 | 4.19 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 5.70 | 6.03 | 9.80 | 11.95 | 25.56 | 16.60 | 15.00 |
| Sundry debtors | 0.00 | 0.05 | 1.90 | 0.53 | 0.88 | 0.30 | 0.20 |
| Cash & bank balances | 0.13 | 0.14 | 0.14 | 0.09 | 0.10 | 0.71 | 0.17 |
| Loans & advances | 3.79 | 4.04 | 5.61 | 3.50 | 8.95 | 3.81 | 3.49 |
| Total current assets | 9.62 | 10.26 | 17.45 | 16.07 | 35.49 | 21.42 | 18.86 |
| Total current liabilities | 51.78 | 52.57 | 51.66 | 38.98 | 67.90 | 37.60 | 42.43 |
| Net working capital | (42.16) | (42.31) | (34.21) | (22.91) | (32.41) | (16.18) | (23.57) |
| Total assets | 111 | 116 | 127 | 136 | 122 | 122 | 91.37 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.14 | 0.14 | 0.09 | 0.10 | 0.71 | 0.17 | 17.32 |
| Net cash from operating activities | (1.92) | (7.89) | 2.36 | (24.71) | (17.22) | (14.57) | (35.50) |
| Net cash from investing activities | (3.64) | (4.97) | (7.82) | (12.65) | (22.90) | (22.55) | (10.22) |
| Net cash from financing activities | 5.54 | 12.86 | 5.50 | 37.34 | 39.51 | 37.66 | 28.58 |
| Net change in cash | (0.01) | 0.00 | 0.05 | (0.01) | (0.61) | 0.54 | (17.14) |
| Closing cash | 0.13 | 0.14 | 0.14 | 0.09 | 0.10 | 0.71 | 0.17 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -45.2% | -14.1% | -3.3% | -12.7% | +11.2% | +60.7% | - |
| EBITDA growth | +63.7% | -72.6% | +44.9% | +53.5% | -93.6% | +5.4% | - |
| PBT growth | +37.1% | -36.5% | +20.2% | +44.5% | -57.1% | +1.8% | -44.4% |
| Net income growth | +37.4% | -37.2% | +20.2% | +44.5% | -57.1% | +1.9% | - |
| Revenue CAGR (3Y) | -23.1% | -10.2% | -2.1% | +16.0% | +7.7% | +16.7% | +117.2% |
| EBITDA CAGR (3Y) | -29.8% | -23.8% | -20.8% | -5.2% | +51.6% | +25.6% | +28.6% |
| Profitability & leverage | |||||||
| Net income margin | -71.4% | -62.2% | -39.1% | -47.4% | -74.6% | -52.8% | -86.4% |
| Return on capital employed | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Return on net worth | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Debt / equity | 0.00 | 0.00 | 2.83 | 0.78 | 2.23 | 0.00 | 0.00 |
| Long-term debt / equity | 0.00 | 0.00 | 2.34 | 0.54 | 1.74 | 0.00 | 0.00 |
| Interest cover | -59.68 | -27.21 | -30.30 | -13.28 | -13.38 | -27.69 | -25.82 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.08 | 0.14 | 0.16 | 0.18 | 0.22 | 0.21 | 0.14 |
| Inventory turnover | 4.05 | 5.47 | 4.64 | 2.78 | 2.83 | 3.40 | 2.79 |
| Debtors turnover | 949.20 | 44.42 | 41.50 | 73.94 | 101.19 | 214.80 | 21.49 |
| EPS (βΉ) | (7.85) | (12.49) | (9.15) | (11.45) | (20.65) | (14.45) | (16.04) |
| Dividend per share (βΉ) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | (75.49) | (67.83) | (55.29) | (46.13) | (34.83) | (23.91) | (13.89) |
Similar companies to Krebs Biochemicals
Krebs Biochemicals has 3 listed similar companies in our database, 2 of them funded. They include Laurus Labs, Symbiotec and SeQuent.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lauruslabs.com | 2005 | Hyderabad, India | $229.73M | 6,035 | Pharmaceutical and biotechnology company | |
| symbiotec.in | 2002 | Indore, India | $61.01M | 1,822 | Non-sterile steroid hormone-based APIs and intermediates are manufactured. | |
| sequent.in | 2002 | Bengaluru, India | APIs are developed and manufactured for therapeutic areas. |
Detailed similar companies of Krebs Biochemicals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Krebs Biochemicals
The website of Krebs Biochemicals (krebsbiochem.com) receives about 1.1K visits a month.
- Monthly visits1.1K
▲ 28.5% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Krebs Biochemicals (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 2,062 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 548 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 557 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Krebs Biochemicals
Complete news archive for Krebs Biochemicals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Krebs Biochemicals
Krebs Biochemicals was founded in 1991.
Krebs Biochemicals is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Krebs Biochemicals has 28 employees.
The primary company behind Krebs Biochemicals, Krebs Biochemicals And Industries Limited, reported revenue of βΉ25.76 Cr for FY 2026, down 45% year on year.
Founded in 1991 and based in Hyderabad, India, Krebs Biochemicals operates in the biopharma sector. Commercially viable biotech processes are developed for applications in medicine and agriculture. Current manufacturing includes Androstenedione as a steroid intermediate, along with Lovastatin and Simvastatin for anti-cholesterol treatments. Products under development encompass amlodipine and Telmisartan for anti-hypertension, Cetirizine for anti-histamine effects, Orlistat for anti-obesity, Serratiopeptidase for anti-inflammatory purposes, and Phenylephrine for cold and cough relief.
Krebs Biochemicals's top competitors include Laurus Labs, Symbiotec and SeQuent.
Krebs Biochemicals offers Biotech Processes.
Yes, Krebs Biochemicals is publicly traded on NSE under the ticker symbol KREBSBIO.
Krebs Biochemicals operates through Krebs Biochemicals And Industries Limited.
The legal entities of Krebs Biochemicals currently have 10 directors, including Avinash Ravi, Ravi Ravindranath Tagore, Pabitrakumar Kalipada Bhattacharyya and others.
